Estimating mean response as a function of treatment duration in an observational study, where duration may be informatively censored.
After a treatment is found to be effective in a clinical study, attention often focuses on the effect of treatment duration on outcome. Such an analysis facilitates recommendations on the most beneficial treatment duration. In many studies, the treatment duration, within certain limits, is left to the discretion of the investigators. It is often the case that treatment must be terminated prematurely due to an adverse event, in which case a recommended treatment duration is part of a policy that treats patients for a specified length of time or until a treatment-censoring event occurs, whichever comes first. Evaluating mean response for a particular treatment-duration policy from observational data is difficult due to censoring and the fact that it may not be reasonable to assume patients are prognostically similar across all treatment strategies. We propose an estimator for mean response as a function of treatment-duration policy under these conditions. The method uses potential outcomes and embodies assumptions that allow consistent estimation of the mean response. The estimator is evaluated through simulation studies and demonstrated by application to the ESPRIT infusion trial coordinated at Duke University Medical Center.
Johnson
Brent A
BA
Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina 27599-7420, USA. bjohnson@bios.unc.edu
Tsiatis
Anastasios A
AA
D001699:Biometry; D002985:Clinical Protocols; D003324:Coronary Artery Disease / Q000188:drug therapy; D003627:Data Interpretation, Statistical; D000077542:Eptifibatide; D006801:Humans; D010455:Peptides / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D013997:Time Factors; D016896:Treatment Outcome
D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D000077542:Eptifibatide